Secreted heat shock protein-90α: A more effective and Safer target for anti-cancer drugs?

Current Signal Transduction Therapy

Volumn 5, Issue 2, 2010, Pages 121-127

  Cheng, Chieh Fang ^a   Fan, Jianhua ^a   Zhao, Zhengwei ^b   Woodley, David T ^a   Li, Wei ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anti cancer target; Cancer progression; Cell migration; HSP90; Secretion

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BECAPLERMIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 ALPHA; ILOMASTAT; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER INVASION; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CELL MOTILITY; CLINICAL TRIAL; DIABETIC FOOT; DIMERIZATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENDOPLASMIC RETICULUM; FIBROBLAST; HUMAN; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

EID: 77953348724     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436210791112208     Document Type: Article

References (54)

1. Lindquist S, Craig EA. The heat-shock proteins. Annu Rev Genet 1988; 22: 631-77.
2. Chen B, Piel WH, Gui L, Bruford E, Monteiro A. The HSP90 family of genes in the human genome: insights into their diver-gence and evolution. Genomics 2005; 86: 627-37.
3. Richter K, Buchner J. Hsp90: chaperoning signal transduction. J Cell Physiol 2001; 188: 281-90.
4. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003; 228: 111-33.
5. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conforma-tion of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Na-ture 2003 25; 425: 407-10.
6. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994; 91: 8324-8.
7. Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin Emerg Drugs 2002; 7: 277-88.
8. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH. Geldanamycin, a new antibiotic. J Antibiot (Tokyo) 1970; 23: 442-7.
9. Grenert JP, Sullivan WP, Fadden P, et al. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 1997 19; 272: 23843-50.
10. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 1995; 36: 305-15.
11. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygel-danamycin in patients with advanced malignancies. J Clin Oncol 2005; 23: 4152-61.
12. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005; 23: 1078-87.
13. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005; 23: 1885-93.
14. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharma-cokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced can-cers. Clin Cancer Res 2005; 11: 3385-91.
15. Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007; 13: 1775-82.
16. Bagatell R, Gore L, Egorin MJ, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 2007; 13: 1783-8.
17. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008; 13: 38-43.
18. Gasc JM, Renoir JM, Radanyi C, Joab I, Tuohimaa P, Baulieu EE. Progesterone receptor in the chick oviduct: an immunohistochemical study with antibodies to distinct receptor components. J Cell Biol 1984; 99: 1193-201.
19. Welch WJ, Feramisco JR. Purification of the major mammalian heat shock proteins. J Biol Chem 1982; 257: 14949-59.
20. Catelli M, Joab I, Renoir J, et al. Immunological studies of chick oviduct progesterone receptor. J Steroid Biochem 1983; 19:134.
21. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther1998; 79: 129-68.
22. Tsutsumi S, Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 2007; 98: 1536-9.
23. Hightower LE, Guidon PT, Jr. Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble gliaaxon transfer proteins. J Cell Physiol 1989; 138: 257-66.
24. Clayton A, Turkes A, Navabi H, Mason MD, Tabi Z. Induction of heat shock proteins in B-cell exosomes. J Cell Sci 2005; 118: 3631-8.
25. Lancaster GI, Febbraio MA. Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J Biol Chem 2005; 280: 23349-55.
26. Liao DF, Jin ZG, Baas AS, et al. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem 2000; 275: 189-96.
27. Yu X, Harris SL, Levine AJ. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res 2006; 66: 4795-801.
28. Li W, Li Y, Guan S, et al. Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. EMBO J 2007; 26: 1221-33.
29. Woodley DT, Fan J, Cheng CF, et al. Participation of the lipoprotein receptor LRP1 in hypoxia-HSP90alpha autocrine signaling to promote keratinocyte migration. J Cell Sci 2009; 122: 1495-8.
30. Cheng CF, Fan J, Fedesco M, et al. Transforming growth factor alpha (TGFalpha)-stimulated secretion of HSP90alpha: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFbeta-rich environment during wound healing. Mol Cell Biol 2008; 28: 3344-58.
31. Simon MC, Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol 2008; 9: 285-96.
32. Kuroita T, Tachibana H, Ohashi H, Shirahata S, Murakami H. Growth stimulating activity of heat shock protein 90 alpha to lymphoid cell lines in serum-free medium. Cytotechnology 1992; 8: 109-17.
33. Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004; 6: 507-14.
34. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000; 113 Pt 19: 3365-74.
35. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002; 2: 569-79.
36. Fevrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 2004; 16: 415-21.
37. Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G. The biogenesis and functions of exosomes. Traffic 2002; 3: 321-30.
38. Mignot G, Roux S, Thery C, Segura E, Zitvogel L. Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med 2006; 10: 376-88.
39. Hegmans JP, Bard MP, Hemmes A, et al. Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol 2004; 164: 1807-15.
40. Savina A, Furlan M, Vidal M, Colombo MI. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem 2003; 278: 20083-90.
41. Tsutsumi S, Scroggins B, Koga F, et al. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 2008 10; 27: 2478-87.
42. Young JC, Moarefi I, Hartl FU. Hsp90: a specialized but essential protein-folding tool. J Cell Biol 2001; 154: 267-73.
43. Sidera K, Samiotaki M, Yfanti E, Panayotou G, Patsavoudi E. Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system. J Biol Chem 2004; 279: 45379-88.
44. Strickland DK, Ashcom JD, Williams S, Burgess WH, Migliorini M, Argraves WS. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem 1990 Oct 15; 265: 17401-4.
45. Kristensen T, Moestrup SK, Gliemann J, Bendtsen L, Sand O, Sottrup-Jensen L. Evidence that the newly cloned low-densitylipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor. FEBS Lett 1990; 276: 151-5.
46. Van Leuven F, Stas L, Raymakers L, et al. Molecular cloning and sequencing of the murine alpha-2-macroglobulin receptor cDNA. Biochim Biophys Acta 1993;1173: 71-4.
47. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001; 14: 303-13.
48. Ogden CA, deCathelineau A, Hoffmann PR, et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001; 194: 781-95.
49. Vandivier RW, Ogden CA, Fadok VA, et al. Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol 2002; 169: 3978-86.
50. Habich C, Baumgart K, Kolb H, Burkart V. The receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins. J Immunol 2002; 168: 569-76.
51. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
52. Bandyopadhyay B, Fan J, Guan S, et al. A "traffic control" role for TGFbeta3: orchestrating dermal and epidermal cell motility during wound healing. J Cell Biol 2006; 172: 1093-105.
53. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341: 738-46.
54. Bachman KE, Park BH. Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter. Curr Opin Oncol 2005; 17: 49-54.